Search
Nemazoline
go.drugbank.com/drugs/DB21115ExperimentalNemazoline has a monoisotopic molecular weight of 243.03 Da. … The usage of the INN stem '-azoline' in the name indicates that Nemazoline is a antihistaminic or local vasoconstrictor, antazoline derivative.
Sinomenine
go.drugbank.com/drugs/DB16892InvestigationalCategories: Heterocyclic Compounds with 4 or More RingsCTx-PDE6b
go.drugbank.com/drugs/DB17858InvestigationalBeing commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.
Satavaptan
go.drugbank.com/drugs/DB14923InvestigationalSatavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).
Hematin
go.drugbank.com/drugs/DB13387InvestigationalCategories: Heterocyclic Compounds with 4 or More RingsIomethin I-125
go.drugbank.com/drugs/DB20779ExperimentalIomethin I-125 has a monoisotopic molecular weight of 353.05 Da.
Calusterone
go.drugbank.com/drugs/DB01564ExperimentalIllicitA Schedule IV drug in Canada.
Synonyms: 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one, 17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-oneADH-1
go.drugbank.com/drugs/DB05485InvestigationalAgents that target and inhibit cadherin function have the potential to attack the progression of cancer at two distinct points: * Direct targeting of cadherins expressed on cancer cells may disturb … Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells and established tumor blood vessels.
Synonyms: l-cysteinamide, n-acetyl-l-cysteinyl-l-histidyl-l-alanyl-l-valyl-, cyclic (1-5)-disulfideHuman papillomavirus type 11 L1 capsid protein antigen
go.drugbank.com/drugs/DB10300ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces
Human papillomavirus type 16 L1 capsid protein antigen
go.drugbank.com/drugs/DB10301ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces